Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
item.page.creator
Johnson, Theodore S.
MacDonald, Tobey J.
Pacholczyk, Rafal
Aguilera, Dolly
Al-Basheer, Ahmad
Bajaj, Manish
Bandopadhayay, Pratiti
Berrong, Zuzana
Bouffet, Eric
Castellino, Robert C.
Dorris, Kathleen
Eaton, Bree R.
Esiashvili, Natia
Fangusaro, Jason R.
Foreman, Nicholas
Fridlyand, Diana
Giller, Cole
Heger, Ian M.
Huang, Chenbin
Kadom, Nadja
Kennedy, Eugene P.
Manoharan, Neevika
Martin, William
McDonough, Colleen
Parker, Rebecca S.
Ramaswamy, Vijay
Ring, Eric
Rojiani, Amyn
Sadek, Ramses F.
Satpathy, Sarthak
Schniederjan, Matthew
Smith, Amy
Smith, Christopher
Thomas, Beena E.
Vaizer, Rachel
Yeo, Kee Kiat
Bhasin, Manoj K.
Munn, David H.
MacDonald, Tobey J.
Pacholczyk, Rafal
Aguilera, Dolly
Al-Basheer, Ahmad
Bajaj, Manish
Bandopadhayay, Pratiti
Berrong, Zuzana
Bouffet, Eric
Castellino, Robert C.
Dorris, Kathleen
Eaton, Bree R.
Esiashvili, Natia
Fangusaro, Jason R.
Foreman, Nicholas
Fridlyand, Diana
Giller, Cole
Heger, Ian M.
Huang, Chenbin
Kadom, Nadja
Kennedy, Eugene P.
Manoharan, Neevika
Martin, William
McDonough, Colleen
Parker, Rebecca S.
Ramaswamy, Vijay
Ring, Eric
Rojiani, Amyn
Sadek, Ramses F.
Satpathy, Sarthak
Schniederjan, Matthew
Smith, Amy
Smith, Christopher
Thomas, Beena E.
Vaizer, Rachel
Yeo, Kee Kiat
Bhasin, Manoj K.
Munn, David H.
Citations
Altmetric:
Soloist
Composer
Publisher
Oxford University Press (OUP)
Date
9/16/2023
Additional date(s)
Abstract
Contents
Subject
Subject(s)
Research Projects
Organizational Units
Journal Issue
Genre
Description
Background. Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy.Methods. We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG). Separate dose-finding arms were performed for indoximod in combination with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles), or with palliative conformal radiation. Blood samples were collected at baseline and monthly for single-cell RNA-sequencing with paired single-cell T cell receptor sequencing.Results. Eighty-one patients were treated with indoximod-based combination therapy. Median follow-up was 52 months (range 39-77 months). Maximum tolerated dose was not reached, and the pediatric dose of indoximod was determined as 19.2 mg/kg/dose, twice daily. Median overall survival was 13.3 months (n = 68, range 0.2-62.7) for all patients with recurrent disease and 14.4 months (n = 13, range 4.7-29.7) for DIPG. The subset of n = 26 patients who showed evidence of objective response (even a partial or mixed response) had over 3-fold longer median OS (25.2 months, range 5.4-61.9, p = 0.006) compared to n = 37 nonresponders (7.3 months, range 0.2-62.7). Four patients remain free of active disease longer than 36 months. Single-cell sequencing confirmed emergence of new circulating CD8 T cell clonotypes with late effector phenotype.Conclusions. Indoximod was well tolerated and could be safely combined with chemotherapy and radiation. Encouraging preliminary evidence of efficacy supports advancing to Phase II/III trials for pediatric brain tumors.
Format
Department
Burnett School of Medicine